The first drug specifically for the treatment of postpartum depression was approved by The Food and Drug Administration. The recently approved drug is called brexanolone. The drug will be advertised as Zulresso. Due to the risk of symptoms caused by the drug including sudden loss of consciousness; therefore, the treatment will only be available as an in-patient at authorized medical centers.

The drug works within 48 hours and is received through a intravenous drip. With the help of the intravenous drop, it helps provide instant relief to women going through the symptoms of post postpartum depression. In the past, postpartum depression has been treated with therapy visits or ordinary antidepressants. Unlike the intravenous drip, antidepressants take several weeks to make a difference compared to the intravenous drip. The treatment will also provide a pill, an easier accessible version than the IV drip, but not as effective. The cost of Zulresso will $34,000 per patient. After patients who were administered Zulresso had less depressive episodes, the Food and Drug Administration passed the new postpartum depression treatment.